Chemotherapy: Pemetrexed

DRUG3 trials

Sponsors

Mirati Therapeutics Inc., Janssen Research & Development, LLC, Jemincare

Conditions

Advanced NSCLCCarcinoma, Non-Small-Cell LungMetastatic Lung CancerNSCLC (Advanced Non-small Cell Lung Cancer)

Phase 1

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

RecruitingNCT06946927

JemincareNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2025-06-06End: 2027-12-31Target: 72Updated: 2025-07-01

Phase 2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

RecruitingNCT05609578

Mirati Therapeutics Inc.Advanced NSCLC, Metastatic Lung Cancer

Start: 2022-11-22End: 2026-12-01Target: 90Updated: 2025-08-17

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

RecruitingNCT06667076

Janssen Research & Development, LLCCarcinoma, Non-Small-Cell Lung

Start: 2024-12-16End: 2030-12-26Target: 480Updated: 2026-03-23

Related Papers

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast.

2025-10-11

Abstract CT233: A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for <i>EGFR</i>-mutated non-small cell lung cancer (NSCLC): COPERNICUS

Cancer Research2025-04-25

Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring <i>KRAS</i>G12Cand <i>STK11</i> mutations: KRYSTAL-1 phase 2 cohort

Cancer Research2025-04-25